Sangamo Therapeutics, Inc.

Historical 13F Holders

Symbol: SGMOQ
CUSIP: 800677106
All holders as of: Q2 2026
Type: Equity
Class: COM

Reported Value, Excluding Options

Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 800677106 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Armistice Capital, LLC 13G/A Amendment 1	9.4%	38,860,819	13G/A Amendment 1	8/14/2026 Event 6/30/2026
Armistice Capital, LLC	9.4%	38,860,819
Steven Boyd	9.4%	38,860,819
Armistice Capital, LLC 13G	9.8%	40,400,067	13G	5/15/2026 Event 3/31/2026
Armistice Capital, LLC	9.8%	40,400,067
Steven Boyd	9.8%	40,400,067
Wasatch Advisors LP 13G/A Amendment 9	2.1%	6,188,358	13G/A Amendment 9	11/12/2025 Event 9/30/2025
Wasatch Advisors LP 13G/A Amendment 8	5.2%	11,630,671	13G/A Amendment 8	5/12/2025 Event 3/31/2025
Wasatch Advisors LP 13G/A Amendment 7	6.6%	13,993,410	13G/A Amendment 7	1/7/2025 Event 12/31/2024

13F Holders by Quarter

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	8	533 k	$29.0 k	$32.9 k
2026 Q1	118	105 M	$26.0 M	$451 k
2025 Q4	112	62.3 M	$26.2 M	$685 k
2025 Q3	121	62.6 M	$42.1 M	$1.39 M
2025 Q2	124	73.8 M	$39.9 M	$1.02 M
2025 Q1	134	52.6 M	$34.5 M	$2.65 M
2024 Q4	141	61.6 M	$62.9 M	$3.55 M
2024 Q3	115	56.2 M	$88.7 M	$1.51 M
2024 Q2	136	87.7 M	$31.4 M	$68.7 k
2024 Q1	139	103 M	$69.8 M	$67.9 k
2023 Q4	137	89.5 M	$48.6 M	$68.4 k
2023 Q3	142	104 M	$62.2 M	$108 k
2023 Q2	155	106 M	$137 M	$131 k
2023 Q1	191	114 M	$200 M	$269 k
2022 Q4	195	114 M	$357 M	$1.43 M
2022 Q3	217	97.8 M	$479 M	$3.89 M
2022 Q2	201	89.7 M	$371 M	$3.29 M
2022 Q1	213	81.1 M	$472 M	$4.87 M
2021 Q4	219	77.4 M	$580 M	$13.2 M
2021 Q3	216	75.3 M	$679 M	$14.7 M
2021 Q2	219	76.2 M	$912 M	$23.0 M
2021 Q1	229	79.4 M	$995 M	$27.3 M
2020 Q4	262	81.3 M	$1.29 B	$67.7 M
2020 Q3	232	81.6 M	$772 M	$21.0 M
2020 Q2	229	77.1 M	$691 M	$19.2 M
2020 Q1	208	74.6 M	$476 M	$11.4 M
2019 Q4	213	80.1 M	$670 M	$16.5 M
2019 Q3	207	84.2 M	$766 M	$22.1 M
2019 Q2	221	82.0 M	$885 M	$64.0 M
2019 Q1	210	66.0 M	$631 M	$30.7 M
2018 Q4	219	65.8 M	$755 M	$34.2 M
2018 Q3	244	67.3 M	$1.14 B	$55.5 M
2018 Q2	230	65.5 M	$930 M	$45.0 M
2018 Q1	224	57.7 M	$1.10 B	$37.1 M
2017 Q4	188	55.8 M	$955 M	$38.3 M
2017 Q3	167	54.9 M	$823 M	$22.8 M
2017 Q2	162	53.0 M	$467 M	$14.9 M
2017 Q1	131	42.2 M	$219 M	$3.24 M
2016 Q4	141	41.9 M	$128 M	$1.66 M
2016 Q3	137	44.0 M	$203 M	$2.92 M
2016 Q2	148	46.5 M	$269 M	$2.61 M
2016 Q1	153	48.7 M	$292 M	$2.46 M
2015 Q4	158	49.1 M	$448 M	$26.9 M
2015 Q3	154	52.7 M	$297 M	$17.3 M
2015 Q2	169	50.7 M	$562 M	$131 M
2015 Q1	182	52.7 M	$826 M	$188 M
2014 Q4	174	49.2 M	$748 M	$197 M
2014 Q3	175	48.8 M	$527 M	$139 M
2014 Q2	169	49.7 M	$760 M	$186 M
2014 Q1	160	48.3 M	$872 M	$244 M